Alnylam Names TTR Amyloidosis Rx as Next IND Candidate, Posts Higher Q2 Losses on Increased Costs
August 13, 2009
Alnylam Names TTR Amyloidosis Rx as Next IND Candidate, Posts Higher Q2 Losses on Increased Costs
Alnylam's selection of ALN-TTR as its next IND candidate comes as no surprise after a company official told RNAi News earlier this summer that it was "highly likely" that the company would choose the drug over other candidates.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Steps Back from Huntington's Drug Deal, Sees Two Partnerships by Year-End
May 10, 2012 / Gene Silencing News - Tekmira Says Pipeline on Track Heading into Q4; Holds Course on Alnylam Litigation
November 10, 2011 / Gene Silencing News - Alnylam Unveils New Vaccine Initiative, Signs GSK as First Partner
November 3, 2011 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News - Alnylam to Release Phase II ATTR Data, Launch Expansion Trial in Coming Months
May 9, 2013 / Gene Silencing News